Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06749691 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Liposomal Irinotecan and Apatinib in ES-SCLC

Study acronym: LIAES
StatusRecruiting
PhasePhase 2
Started2024-12-28
View on ClinicalTrials.gov ↗
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.

Amendment history 1 change detected by DataLookout

2026-08-09
notable
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
WasSecond Affiliated Hospital, School of Medicine, Zhejiang University
NowSecond Affiliated Hospital, Zhejiang University, School of Medicine
Trial Details
NCT Number NCT06749691
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Small Cell Lung Cancer Extensive Stage
Enrollment 30 participants
Start Date 2024-12-28
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-27